1
|
Erdal E, Bakici C, Arslan A, Batur B, Yaman ME, Alçığır ME, Akyol M, Ekim O, Salih B, Uğurlu N. Ocular pharmacokinetics and toxicity of nanoparticular acetazolamide: In vivo distribution and safety of PHBV-ACZ nanoparticle. Int J Pharm 2023; 645:123336. [PMID: 37598873 DOI: 10.1016/j.ijpharm.2023.123336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 08/16/2023] [Accepted: 08/17/2023] [Indexed: 08/22/2023]
Abstract
Diabetic macular edema (DME) is defined as fluid accumulation in the macular region, between the retinal layers, due to many diseases, especially diabetes. DME is one of the major complications of diabetic retinopathy (DRP). Carbonic anhydrase inhibitors (CAI) are a pharmaceutical agent used in different fields, especially glaucoma treatment. Acetazolamide (ACZ), which is a CAI, is an active substance that has been used off-label for many years in the treatment of macular edema due to diabetes and many other diseases. The low solubility and bioavailability of ACZ limit its use in the treatment of DME. In this study, a nanoparticulate formulation was developed that would increase the solubility and bioavailability of ACZ and allow it to be administered intravitreally. ACZ was loaded on poly(3-hydroxybutyrate-co-3-Hydroxyvalerate) (PHBV) nanoparticles and the loading efficiency was 71.58 ± 1.22%. Toxicity of nanoparticles after intravitreal application was evaluated with anterior segment and posterior segment examination findings, intraocular pressure (IOP) measurements and electrophysiological tests. At the end of the 3-month follow-up, electroretinography (ERG) measurements demonstrated that ACZ loaded PHBV (PHBV-ACZ) nanoparticles did not cause loss of function in retinal cells. On histological examination, rare degenerative changes were observed in several cell groups. In addition, pharmacokinetic studies were performed to determine the tissue distribution of ACZ at various periods. ACZ was identified in vitreous humor and retina at the highest concentration. Based on our results, the prepared nanoparticle formulation can release long-term CAI for DRP therapy and accordingly can reduce the need for monthly intravitreal injections.
Collapse
Affiliation(s)
- Ebru Erdal
- Faculty of Medicine, Advanced Technologies Application and Research Center, Ankara Yıldırım Beyazıt University, 06800 Ankara, Turkey
| | - Caner Bakici
- Faculty of Veterinary Medicine, Department of Anatomy, Ankara University, 06110 Ankara, Turkey
| | - Aslıhan Arslan
- School of Pharmacy, Medical Biology Center, Queen's University Belfast, Northern, Ireland, UK
| | - Barış Batur
- Faculty of Veterinary Medicine, Department of Anatomy, Ankara University, 06110 Ankara, Turkey; Graduate School of Health Sciences, Ankara University, Ankara, Turkey
| | - Mehmet Emrah Yaman
- Faculty of Pharmacy, Department of Analytical Chemistry, Ataturk University, 25240 Erzurum, Turkey
| | - Mehmet Eray Alçığır
- Faculty of Veterinary Medicine, Department of Pathology, Kirikkale University, 71450 Kirikkale, Turkey
| | - Mesut Akyol
- Department of Biostatistics and Medical Informatics, Ankara Yildirim Beyazit University, 06800 Ankara, Turkey
| | - Okan Ekim
- Faculty of Veterinary Medicine, Department of Anatomy, Ankara University, 06110 Ankara, Turkey
| | - Bekir Salih
- Department of Chemistry, Hacettepe University, 06800 Ankara, Turkey
| | - Nagihan Uğurlu
- Faculty of Medicine, Advanced Technologies Application and Research Center, Ankara Yıldırım Beyazıt University, 06800 Ankara, Turkey; Department of Ophtalmology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, 06800, Turkey.
| |
Collapse
|
2
|
Bąk U, Krupa A. Challenges and Opportunities for Celecoxib Repurposing. Pharm Res 2023; 40:2329-2345. [PMID: 37552383 PMCID: PMC10661717 DOI: 10.1007/s11095-023-03571-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 07/18/2023] [Indexed: 08/09/2023]
Abstract
Drug repositioning, also known as drug repurposing, reprofiling, or rediscovery, is considered to be one of the most promising strategies to accelerate the development of new original drug products. Multiple examples of successful rediscovery or therapeutic switching of old molecules that did not show clinical benefits or safety in initial trials encourage the following of the discovery of new therapeutic pathways for them. This review summarizes the efforts that have been made, mostly over the last decade, to identify new therapeutic targets for celecoxib. To achieve this goal, records gathered in MEDLINE PubMed and Scopus databases along with the registry of clinical trials by the US National Library of Medicine at the U.S. National Institutes of Health were explored. Since celecoxib is a non-steroidal anti-inflammatory drug that represents the class of selective COX-2 inhibitors (coxibs), its clinical potential in metronomic cancer therapy, the treatment of mental disorders, or infectious diseases has been discussed. In the end, the perspective of a formulator, facing various challenges related to unfavorable physicochemical properties of celecoxib upon the development of new oral dosage forms, long-acting injectables, and topical formulations, including the latest trends in the pharmaceutical technology, such as the application of mesoporous carriers, biodegradable microparticles, lipid-based nanosystems, or spanlastics, was presented.
Collapse
Affiliation(s)
- Urszula Bąk
- Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688, Cracow, Poland
| | - Anna Krupa
- Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688, Cracow, Poland.
| |
Collapse
|
3
|
Nashine S. Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). Cells 2021; 10:cells10092483. [PMID: 34572131 PMCID: PMC8464988 DOI: 10.3390/cells10092483] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 09/02/2021] [Accepted: 09/09/2021] [Indexed: 12/27/2022] Open
Abstract
Aging contributes to the risk of development of ocular diseases including, but not limited to, Age-related Macular Degeneration (AMD) that is a leading cause of blindness in the United States as well as worldwide. Retinal aging, that contributes to AMD pathogenesis, is characterized by accumulation of drusen deposits, alteration in the composition of Bruch’s membrane and extracellular matrix, vascular inflammation and dysregulation, mitochondrial dysfunction, and accumulation of reactive oxygen species (ROS), and subsequent retinal pigment epithelium (RPE) cell senescence. Since there are limited options available for the prophylaxis and treatment of AMD, new therapeutic interventions are constantly being looked into to identify new therapeutic targets for AMD. This review article discusses the potential candidates for AMD therapy and their known mechanisms of cytoprotection in AMD. These target therapeutic candidates include APE/REF-1, MRZ-99030, Ciliary NeuroTrophic Factor (CNTF), RAP1 GTPase, Celecoxib, and SS-31/Elamipretide.
Collapse
Affiliation(s)
- Sonali Nashine
- Department of Ophthalmology, University of California Irvine, Irvine, CA 92697, USA
| |
Collapse
|
4
|
Blazaki S, Tsika C, Tzatzarakis M, Naoumidi E, Tsatsakis A, Tsatsanis C, Tsilimbaris MK. Pharmacokinetics and efficacy of intraocular flurbiprofen. Graefes Arch Clin Exp Ophthalmol 2017; 255:2375-2380. [DOI: 10.1007/s00417-017-3812-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 09/05/2017] [Accepted: 09/18/2017] [Indexed: 11/28/2022] Open
|
5
|
Pachis K, Blazaki S, Tzatzarakis M, Klepetsanis P, Naoumidi E, Tsilimbaris M, Antimisiaris SG. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation. Eur J Pharm Sci 2017; 109:324-333. [PMID: 28843864 DOI: 10.1016/j.ejps.2017.08.028] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 07/30/2017] [Accepted: 08/22/2017] [Indexed: 12/18/2022]
Abstract
A novel Flurbiprofen (FLB)-in-liposome-in-hydrogel formulation was developed, as a method to sustain the release and increase the ocular bioavailability of FLB following intravitreal injection. For this, FLB loading into liposomes was optimized and liposomes were entrapped in thermosensitive hydrogels consisted of Pluronic F-127 (P). FLB solution, liposomes, and FLB dissolved in hydrogel were also used as control formulations. Actively loaded liposomes were found to be optimal for high FLB loading and small size, while in vitro studies revealed that P concentration of 18% (w/v) was best to retain the integrity of the hydrogel-dispersed liposome, compared to a 20% concentration. The in vitro release of FLB was significantly sustained when FLB-liposomes were dispersed in the hydrogel compared to hydrogel dissolved FLB, as well as the other control formulations. In vivo studies were carried out in pigmented rabbits which were injected through a 27G needle with 1mg/mL FLB in the different formulation-types. Ophthalmic examinations after intravitreal injection of all FLB formulations, revealed no evidence of inflammation, hemorrhage, uveitis or endophthalmitis. Pharmacokinetic analysis results confirm that the hybrid drug delivery system increases the bioavailability (by 1.9 times compared to solution), and extends the presence of the drug in the vitreous cavity, while liposome and hydrogel formulations demonstrate intermediate performance. Furthermore the hybrid system increases MRT of FLB in aqueous humor and retina/choroid tissues, compared to all the control formulations. Currently the potential therapeutic advances of FLB sustained release formulations for IVT administration are being evaluated.
Collapse
Affiliation(s)
- K Pachis
- Laboratory of Pharmaceutical Technology, Dept. of Pharmacy, University of Patras, Rio 26510, Patras, Greece
| | - S Blazaki
- Laboratory of Optics and Vision, Department of Medicine, University of Crete, Heraklion, Greece
| | - M Tzatzarakis
- Laboratory of Toxicology, Medical School, University of Crete, Heraklion, Greece
| | - P Klepetsanis
- Laboratory of Pharmaceutical Technology, Dept. of Pharmacy, University of Patras, Rio 26510, Patras, Greece; Institute of Chemical Engineering, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Platani 26504, Greece
| | - E Naoumidi
- Laboratory of Optics and Vision, Department of Medicine, University of Crete, Heraklion, Greece
| | - M Tsilimbaris
- Laboratory of Optics and Vision, Department of Medicine, University of Crete, Heraklion, Greece.
| | - S G Antimisiaris
- Laboratory of Pharmaceutical Technology, Dept. of Pharmacy, University of Patras, Rio 26510, Patras, Greece; Institute of Chemical Engineering, Foundation for Research and Technology Hellas, FORTH/ICE-HT, Platani 26504, Greece.
| |
Collapse
|
6
|
Changes in Retinal Function and Cellular Remodeling Following Experimental Retinal Detachment in a Rabbit Model. J Ophthalmol 2017; 2017:4046597. [PMID: 28491466 PMCID: PMC5401754 DOI: 10.1155/2017/4046597] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 01/29/2017] [Accepted: 02/13/2017] [Indexed: 11/17/2022] Open
Abstract
Purpose. To explore functional electroretinographic (ERG) changes and associated cellular remodeling following experimental retinal detachment in a rabbit model. Methods. Retinal detachment was created in ten rabbits by injecting 0.1 ml balanced salt solution under the retina. Fundus imaging was performed 0, 3, 7, 14, and 21 days postoperatively. ERGs were recorded pre- and 7 and 21 days postoperatively. Eyes were harvested on day 21 and evaluated immunohistochemically (IHC) for remodeling of second- and third-order neurons. Results. Retinal reattachment occurred within two weeks following surgery. No attenuation was observed in the photopic or scotopic a- and b-waves. A secondary wavefront on the descending slope of the scotopic b-wave was the only ERG result that was attenuated in detached retinas. IHC demonstrated anatomical changes in both ON and OFF bipolar cells. Bassoon staining was observed in the remodeled dendrites. Amacrine and horizontal cells did not alter, but Muller cells were clearly reactive with marked extension. Conclusion. Retinal detachment and reattachment were associated with functional and anatomical changes. Exploring the significance of the secondary scotopic wavefront and its association with the remodeling of 2nd- and 3rd-order neurons will shade more light on functional changes and recovery of the retina.
Collapse
|
7
|
Test–retest reliability of scotopic full-field electroretinograms in rabbits. Doc Ophthalmol 2017; 134:157-165. [DOI: 10.1007/s10633-017-9582-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 03/01/2017] [Indexed: 10/20/2022]
|
8
|
Salazar-Méndez R, Yilmaz T, Cordero-Coma M. Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development. Expert Opin Investig Drugs 2015; 25:195-214. [DOI: 10.1517/13543784.2016.1128893] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
9
|
Yavuz B, Pehlivan SB, Vural İ, Ünlü N. In Vitro/In Vivo Evaluation of Dexamethasone—PAMAM Dendrimer Complexes for Retinal Drug Delivery. J Pharm Sci 2015; 104:3814-3823. [DOI: 10.1002/jps.24588] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Revised: 05/31/2015] [Accepted: 06/29/2015] [Indexed: 01/29/2023]
|